1.ShengJing Hospital, China Medical University, Liaoning Province, Shenyang 110000, China;
2.Department of Sports Medicine, Yuncheng Central Hospital, Shanxi Province, Yuncheng 044000, China;
3.School of Basic Medicine, China Medical University, Liaoning Province, Shenyang 110000, China
Abstract：Osteoporosis is one of the global health problems, which seriously affects the health and quality of life of patients. Bisphosphonates are currently the first-line drugs recommended by the international community for the treatment of osteoporosis. As the third-generation bisphosphonates, Zoledronic Acid is widely used in clinical practice because of its strong anti-bone resorption effect and effective relief of osteoporosis symptoms. However, with the deepening of research, more and more medical workers have pointed out in their reports that there are many kinds of adverse reactions when using Zoledronic Acid, and the incidence of acute phase reaction, osteonecrosis of the jaw, ocular complications, kidney injury, hypocalcemia and other adverse reactions is higher or the symptoms are more serious in clinical practice. In this paper, the mechanism, adverse reactions and their influencing factors, prevention and control of adverse reactions of Zoledronic Acid in the treatment of osteoporosis are reviewed to provide a reference for clinical use of Zoledronic Acid.
吴鸿亮1* 郑思杭1* 景胜杰2 邢睿达3 龚贺龙1 田野1. 唑来膦酸治疗骨质疏松不良反应影响因素及防治的研究进展[J]. 中国医药导报, 2021, 18(23): 38-42.
WU Hongliang1* ZHENG Sihang1* JING Shengjie2 XING Ruida3 GONG Helong1 TIAN Ye1. Research progress on influencing factors and prevention of adverse reactions of Zoledronic Acid in the treatment of osteoporosis. 中国医药导报, 2021, 18(23): 38-42.
[1] 夏维波，章振林，林华，等.原发性骨质疏松症诊疗指南（2017）[J].中国骨质疏松杂志，2019，25（3）：281-309.
[2] 中国骨质疏松症流行病学调查及“健康骨骼”专项行动结果发布[J].中华骨质疏松和骨矿盐疾病杂志，2019，12（4）：317-318.
[3] Johnell O，Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures [J]. Osteoporos Int，2006，17（12）：1726-1733.
[4] Barbanente A，Gandin V，Ditaranto N，et al. A Pt（Ⅳ） prodrug of kiteplatin with the bone-targeting pyrophosphate ligand [J]. Inorganica Chim Acta，2019：494.
[5] Russell R，Graham G. Bisphosphonates：the first 40 years [J]. Bone，2011，49（1）：2-19.
[6] Black DM，Delmas PD，Eastell R，et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis [J]. N Engl J Med，2007，356（18）：1893.
[7] Lyles KW，Colón-Emeric CS，Magaziner JS，et al. Zoledronic acid and clinical fractures and mortality after hip fracture [J]. N Engl J Med，2007，357（18）：1799-809.
[8] Rogers MJ，M?觟nkk?觟nen J，Munoz MA. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton [J]. Bone，2020，139：115493.
[9] Jin ZH，Wang SF，Liao W. Zoledronic acid accelerates osteogenesis of bone marrow mesenchymal stem cells by attenuating oxidative stress via the SIRT3/SOD2 pathway and thus alleviates osteoporosis [J]. Eur Rev Med Pharmacol Sci，2020，24（4）：2095-2101.
[10] 沈佶，吴惠英，边平达，等.老年骨质疏松患者唑来膦酸急性期反应与性别和双膦酸盐类药物使用史的关系[J].中国医药，2020，15（2）：288-291.
[11] Welton JL，Morgan MP，Martí S，et al. Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate：insights from a phase IV safety trial [J]. J Bone Miner Res，2013，28（3）：464-471.
[12] 李季，赵方，赵维彪，等.唑来膦酸治疗老年患者高转换型骨质疏松症的临床效果及其对骨代谢标志物的影响[J].中国骨质疏松杂志，2020，26（10）：1519-1522， 1527.
[13] Hoff AO，Toth BB，Altundag K，et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates [J]. J Bone Miner Res，2008，23（6）：826-836.
[14] Kizub DA，Miao J，Schubert MM，et al. Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer （SWOG 0307） [J]. Support Care Cancer，2021，29（5）：2509-2517.
[15] Hoefert S，Schmitz I，Tannapfel A，et al. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw：a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings[J]. Clin Oral Investig，2010，14（3）：271-284.
[16] Tan YL，Sims J，Chee SP. Bilateral uveitis secondary to bisphosphonate therapy [J]. Ophthalmologica，2009，223（3）：215-216.
[17] 王庆，顾鸣宇，黄景彬，等.唑来膦酸疑致上眼睑水肿、下垂伴结膜炎1例[J].中南药学，2020，18（7）：1270-1272.
[18] 张俊越，龚维明.唑来膦酸注射液治疗骨质疏松不良反应的研究进展[J].山东医药，2020，60（13）：107-110.
[19] Lan Z，Chai K，Jiang Y，et al. Characterization of urinary biomarkers and their relevant mechanisms of zoledronate-induced nephrotoxicity using rats and HK-2 cells [J]. Hum Exp Toxicol，2019，38（5）：598-609.
[20] Cheng L，Ge M，Lan Z，et al. Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity[J]. Arch Toxicol，2018，92（1）：469-485.
[21] Umunakwe OC，Herren D，Kim SJ，et al. Diffuse ocular and orbital inflammation after zoledronate infusion-case report and review of the literature [J]. Digit J Ophthalmol，2017，23（4）：18-21.
[22] Gupta S，Onkar A，Vashisht T. Zoledronic acid induced unilateral anterior uveitis [J]. Indian J Ophthalmol，2020，68（9）：2002-2003.
[23] 单慧亭，陈春燕，吉鹏，等.首次注射唑来膦酸治疗骨质疏松症所致发热及相关因素分析[J].中南药学，2021， 19（2）：346-350.
[24] 樊实真.唑来膦酸注射液治疗高龄老年性骨质疏松的药物不良反应分析[J].数理医药学杂志，2021，34（5）：699-701.
[25] 张俐，杨云龙，崔妍，等.高龄老年骨质疏松患者骨代谢特点及初次接受唑来膦酸治疗后急性期不良反应观察[J].中国骨质疏松杂志，2018，24（10）：1337-1340， 1374.
[26] 杨立进，林涌鹏，陈博来，等.唑来膦酸的使用次数与骨密度及临床疗效的相关性[J].广东医学 2018，39（9）：1410-1414.
[27] Rossini M，Adami S，Viapiana O，et al. Long-term effects of amino-bisphosphonates on circulating γδ T cells [J]. Calcif Tissue Int，2012，91（6）：395-399.
[28] Crotti C，Watts NB，De Santis M，et al. Acute phase reactions after zoledronic acid infusion：protective role of 25-hydroxyvitamin D and Previous oral bisphosphonate Therapy [J]. Endocr Pract，2018，24（5）：405-410.
[29] Popp AW，Senn R，Curkovic I，et al. Factors associated with acute-phase response of bisphosphonate-na?觙ve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate [J]. Osteoporos Int，2017，28（6）：1995-2002.
[30] Chen L，Cencioni MT，Angelini DF，et al. Transcriptional profiling of gamma delta T cells identifies a role for vitamin D in the immunoregulation of the V gamma 9V delta 2 response to phosphate-containing ligands [J]. J Immunol，2005，174（10）：6144-6152.
[31] De Santis M，Cavaciocchi F，Ceribelli A，et al. Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation：the case of zoledronic acid-induced acute phase reaction [J]. Lupus，2015，24（4-5）：442-447.
[32] Rossini M，Adami S，Viapiana O，et al. Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration [J]. J Bone Miner Res，2012， 27（1）：227-230.
[33] Liu Z，Li CW，Mao YF，et al. Study on Zoledronic Acid Reducing Acute Bone Loss and Fracture Rates in Elderly Postoperative Patients with Intertrochanteric Fractures [J]. Orthop Surg，2019，11（3） ：380-385.
[34] 杨琼，于亮，赵刘军，等.复方对乙酰氨基酚片对绝经后骨质疏松症伴骨折患者首次唑来膦酸治疗急性期反应的预防效果[J].中国乡村医药，2020，27（9）：13-14.
[35] Jiang H，Ti YF，Wang YC，et al. Downregulation of regulatory T cell function in patients with delayed fracture healing [J]. Clin Exp Pharmacol Physiol，2018，45（5）：430-436.
[36] 浦祥玲，黄辰羊，张悠扬，等.绝经后骨质疏松静滴唑来膦酸急性期发热相关因素分析[J].中国骨质疏松杂志，2018，24（10）：1273-1277，1316.
[37] 蔡建，吴璠.双膦酸盐预治疗减少首次应用唑来膦酸的短期不良反应效果研究[J].中国现代药物应用，2019， 13（2）：136-138.
[38] Nakagawa T，Ohta K，Uetsuki R，et al. Zoledronate Inhibits Osteoclast Differentiation via Suppressing Vascular Endothelial Growth Factor Receptor 2 Expression [J]. Biochem Genet，2020，58（3）：473-489.
[39] 吴蕊，朱丛丛，李晓宇，等.改良水化方法对唑来膦酸注射液急性期反应的影响[J].药物不良反应杂志，2019（6）：420-424.
[40] 李玉萍，刘方，孙睆睆.口服水化对减轻骨质疏松症患者首次注射唑来膦酸不良反应的疗效分析[J].河南医学高等专科学校学报，2020，32（5）：565-567.
[41] Dai X，Deng Y，Luo Y，et al. Effect of different hydration doses on renal function in patients with primary osteoporosis treated with zoledronic acid：A hospital-based retrospective cohort study [J]. Medicine （Baltimore），2020， 99（25）：e20831.
[42] 武磊.塞来昔布预防唑来膦酸治疗老年性骨质疏松症不良反应的疗效观察[J].临床合理用药杂志，2019，12（28）：72-73.
[43] 蔡学峰，沈晓峰.醋酸钙和维生素D治疗骨质疏松症的研究[J].中外医疗，2020，39（19）：100-101，110.
[44] Lisnyansky M，Kapelushnik N，Ben-Bassat A，et al. Reduced Activity of Geranylgeranyl Diphosphate Synthase Mutant Is Involved in Bisphosphonate-Induced Atypical Fractures [J]. Mol Pharmacol，2018，94（6）：1391-1400.
[45] Anagnostis P，Paschou SA，Mintziori G，et al. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis：EMAS position statement [J]. Maturitas，2017，101：23-30.
京公网安备 11010502046598号